Drug intelligence / Profile preview

PN-107

Development stage: Preclinical
Lead developer: Axcella
Modality: Peptides
Administration: Oral

Overview

PN-107 is a clinical-stage oral biologic developed by Pronutria Biosciences (now Axcella Health). It is a disease-specific amino acid composition designed to regulate amino acid imbalances and restore cellular homeostasis. The drug is being developed for the treatment and prevention of serious conditions linked to amino acid imbalances, including muscle loss (sarcopenia and cachexia conditions like anorexia, chronic obstructive pulmonary disease, and congestive heart failure), metabolic disorders, neurological diseases, and liver conditions.

Beyond the preview

Go deeper on PN-107.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on PN-107.

Explore the full profile